The late phase of preconditioning

Roberto Bolli

Research output: Contribution to journalArticle

Abstract

Unlike the early phase of preconditioning (PC), which lasts 2 to 3 hours and protects against infarction but not against stunning, the late phase of PC lasts 3 to 4 days and protects against both infarction and stunning, suggesting that it may have greater clinical relevance. It is now clear that late PC is a polygenic phenomenon that requires the simultaneous activation of multiple stress-responsive genes. Chemical signals released by a sublethal ischemic stress (such as NO, reactive oxygen species, and adenosine) trigger a complex cascade of signaling events that includes the activation of protein kinase C, Src protein tyrosine kinases, and nuclear factor κB and culminates in increased synthesis of inducible NO synthase, cyclooxygenase-2, aldose reductase, Mn superoxide dismutase, and probably other cardioprotective proteins. An analogous sequence of events can be triggered by a variety of stimuli, such as heat stress, exercise, and cytokines. Thus, late PC appears to be a universal response of the heart to stress in general. Importantly, the cardioprotective effects of late PC can be reproduced pharmacologically with clinically relevant agents (eg, NO donors, adenosine receptor agonists, endotoxin derivatives, or opioid receptor agonists), suggesting that this phenomenon might be exploited for therapeutic purposes. The purpose of this review is to summarize current information regarding the pathophysiology and mechanism of late PC.

Original languageEnglish (US)
Pages (from-to)972-983
Number of pages12
JournalCirculation Research
Volume87
Issue number11
StatePublished - Nov 24 2000
Externally publishedYes

Fingerprint

Infarction
Purinergic P1 Receptor Agonists
Aldehyde Reductase
src-Family Kinases
Opioid Receptors
Cyclooxygenase 2
Nitric Oxide Synthase
Adenosine
Protein Kinase C
Superoxide Dismutase
Reactive Oxygen Species
Hot Temperature
Cytokines
Genes
Proteins
Therapeutics
endotoxin receptor

Keywords

  • Aldose reductase
  • Cyclooxygenase
  • Myocardial ischemia
  • Myocardial reperfusion
  • Nitric oxide

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Bolli, R. (2000). The late phase of preconditioning. Circulation Research, 87(11), 972-983.

The late phase of preconditioning. / Bolli, Roberto.

In: Circulation Research, Vol. 87, No. 11, 24.11.2000, p. 972-983.

Research output: Contribution to journalArticle

Bolli, R 2000, 'The late phase of preconditioning', Circulation Research, vol. 87, no. 11, pp. 972-983.
Bolli R. The late phase of preconditioning. Circulation Research. 2000 Nov 24;87(11):972-983.
Bolli, Roberto. / The late phase of preconditioning. In: Circulation Research. 2000 ; Vol. 87, No. 11. pp. 972-983.
@article{ec0b5aadaeb9461d9d44ebe641ab4104,
title = "The late phase of preconditioning",
abstract = "Unlike the early phase of preconditioning (PC), which lasts 2 to 3 hours and protects against infarction but not against stunning, the late phase of PC lasts 3 to 4 days and protects against both infarction and stunning, suggesting that it may have greater clinical relevance. It is now clear that late PC is a polygenic phenomenon that requires the simultaneous activation of multiple stress-responsive genes. Chemical signals released by a sublethal ischemic stress (such as NO, reactive oxygen species, and adenosine) trigger a complex cascade of signaling events that includes the activation of protein kinase C, Src protein tyrosine kinases, and nuclear factor κB and culminates in increased synthesis of inducible NO synthase, cyclooxygenase-2, aldose reductase, Mn superoxide dismutase, and probably other cardioprotective proteins. An analogous sequence of events can be triggered by a variety of stimuli, such as heat stress, exercise, and cytokines. Thus, late PC appears to be a universal response of the heart to stress in general. Importantly, the cardioprotective effects of late PC can be reproduced pharmacologically with clinically relevant agents (eg, NO donors, adenosine receptor agonists, endotoxin derivatives, or opioid receptor agonists), suggesting that this phenomenon might be exploited for therapeutic purposes. The purpose of this review is to summarize current information regarding the pathophysiology and mechanism of late PC.",
keywords = "Aldose reductase, Cyclooxygenase, Myocardial ischemia, Myocardial reperfusion, Nitric oxide",
author = "Roberto Bolli",
year = "2000",
month = "11",
day = "24",
language = "English (US)",
volume = "87",
pages = "972--983",
journal = "Circulation Research",
issn = "0009-7330",
publisher = "Lippincott Williams and Wilkins",
number = "11",

}

TY - JOUR

T1 - The late phase of preconditioning

AU - Bolli, Roberto

PY - 2000/11/24

Y1 - 2000/11/24

N2 - Unlike the early phase of preconditioning (PC), which lasts 2 to 3 hours and protects against infarction but not against stunning, the late phase of PC lasts 3 to 4 days and protects against both infarction and stunning, suggesting that it may have greater clinical relevance. It is now clear that late PC is a polygenic phenomenon that requires the simultaneous activation of multiple stress-responsive genes. Chemical signals released by a sublethal ischemic stress (such as NO, reactive oxygen species, and adenosine) trigger a complex cascade of signaling events that includes the activation of protein kinase C, Src protein tyrosine kinases, and nuclear factor κB and culminates in increased synthesis of inducible NO synthase, cyclooxygenase-2, aldose reductase, Mn superoxide dismutase, and probably other cardioprotective proteins. An analogous sequence of events can be triggered by a variety of stimuli, such as heat stress, exercise, and cytokines. Thus, late PC appears to be a universal response of the heart to stress in general. Importantly, the cardioprotective effects of late PC can be reproduced pharmacologically with clinically relevant agents (eg, NO donors, adenosine receptor agonists, endotoxin derivatives, or opioid receptor agonists), suggesting that this phenomenon might be exploited for therapeutic purposes. The purpose of this review is to summarize current information regarding the pathophysiology and mechanism of late PC.

AB - Unlike the early phase of preconditioning (PC), which lasts 2 to 3 hours and protects against infarction but not against stunning, the late phase of PC lasts 3 to 4 days and protects against both infarction and stunning, suggesting that it may have greater clinical relevance. It is now clear that late PC is a polygenic phenomenon that requires the simultaneous activation of multiple stress-responsive genes. Chemical signals released by a sublethal ischemic stress (such as NO, reactive oxygen species, and adenosine) trigger a complex cascade of signaling events that includes the activation of protein kinase C, Src protein tyrosine kinases, and nuclear factor κB and culminates in increased synthesis of inducible NO synthase, cyclooxygenase-2, aldose reductase, Mn superoxide dismutase, and probably other cardioprotective proteins. An analogous sequence of events can be triggered by a variety of stimuli, such as heat stress, exercise, and cytokines. Thus, late PC appears to be a universal response of the heart to stress in general. Importantly, the cardioprotective effects of late PC can be reproduced pharmacologically with clinically relevant agents (eg, NO donors, adenosine receptor agonists, endotoxin derivatives, or opioid receptor agonists), suggesting that this phenomenon might be exploited for therapeutic purposes. The purpose of this review is to summarize current information regarding the pathophysiology and mechanism of late PC.

KW - Aldose reductase

KW - Cyclooxygenase

KW - Myocardial ischemia

KW - Myocardial reperfusion

KW - Nitric oxide

UR - http://www.scopus.com/inward/record.url?scp=0034711508&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034711508&partnerID=8YFLogxK

M3 - Article

C2 - 11090541

AN - SCOPUS:0034711508

VL - 87

SP - 972

EP - 983

JO - Circulation Research

JF - Circulation Research

SN - 0009-7330

IS - 11

ER -